Efficacy and safety of once-weekly semaglutide was evaluated in the SUSTAIN series trials in which adults with type 2 diabetes were randomized to semaglutide 0.5 mg and semaglutide 1.0 mg and comparator (placebo, sitagliptin, insulin glargine, other GLP-1 agonists) medical treatments with primary endpoint being reduction of glycated haemoglobin and secondary endpoint being weight loss. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.